Stock Events

Stock Events

IN8bio 

$1.48
0
+$0.13+9.63% Wednesday 07:56

Statistics

Day High
1.48
Day Low
1.48
52W High
-
52W Low
-
Volume
20
Avg. Volume
-
Mkt Cap
6.86M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-1.08
-0.87
-0.66
-0.45
Expected EPS
-0.5438
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-60.87MNet Income

Analyst Ratings

$6.00Average Price Target
The highest estimate is 6.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INAB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with IN8bio in the development of cancer therapies, including cell therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes in the oncology sector, particularly in the development of innovative cancer treatments similar to IN8bio's focus.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in the discovery, development, and delivery of cancer treatments, competing directly with IN8bio in the oncology space.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is focused on the development of allogeneic CAR T therapies for cancer, competing in the same space as IN8bio.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including for cancer, which puts it in competition with IN8bio's cell therapy approach.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad oncology portfolio, competing across various aspects of cancer treatment, including areas targeted by IN8bio.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicine, including gene therapy for cancer, competing with IN8bio in the innovative treatment space.

About

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Show more...
CEO
ISIN
US45674E2081

Listings

F
DE
6JH0.F
XNAS
US
INAB
BOATS
BOATS
INAB.BOATS

0 Comments

Share your thoughts

FAQ

What is IN8bio stock price today?▼
The current price of INAB.BOATS is $1.48 USD — it has increased by +9.63% in the past 24 hours. Watch IN8bio stock price performance more closely on the chart.
What is IN8bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IN8bio stocks are traded under the ticker INAB.BOATS.
What is IN8bio market cap?▼
Today IN8bio has the market capitalization of 6.86M
When is the next IN8bio earnings date?▼
IN8bio is going to release the next earnings report on May 07, 2026.
What were IN8bio earnings last quarter?▼
INAB.BOATS earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.64 USD resulting in a +29.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IN8bio revenue for the last year?▼
IN8bio revenue for the last year amounts to 0 USD.
What is IN8bio net income for the last year?▼
INAB.BOATS net income for the last year is -60.87M USD.
When did IN8bio complete a stock split?▼
IN8bio has not had any recent stock splits.